Video

Q&A With Gilmore O'Neill of Biogen International: Tecfidera as MS Treatment Leader

Author(s):

Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.

Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.

Gilmore O'Neill, MD, of Biogen International discussed what has made the medication a go to choice for doctors and patients alike during the American Academy of Neurology's annual meeeting in Washington, DC. O'Neill also discussed the safety profile for the medication and the advantages of Tecfidera being an oral treatment option.

Related Videos
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
© 2025 MJH Life Sciences

All rights reserved.